Nahla Hasabou

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Neal D. Shore, Simon Chowdhury, Arnauld Villers et al. · The Lancet Oncology · 2016 · 283 citations

Medicine, Oncology, Pharmacology +14

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J. Levis, Mehdi Hamadani, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 185 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev et al. · Blood · 2022 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Spectroscopic Microvascular Blood Detection From the Endoscopically Normal Colonic Mucosa: Biomarker for Neoplasia Risk

Hemant K. Roy, Andrew Gomes, Vladimir Turzhitsky et al. · Gastroenterology · 2008 · 65 citations · Full text

Medicine, Oncology, Pathology +14